- Home
- NCMI vs RNA Comparison
NCMI vs RNA Comparison
Compare NCMI & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCMI | RNA |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.0M | 222.5M |
| IPO Year | 2006 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NCMI | RNA |
|---|---|---|
| Price | $2.27 | $8.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 20 |
| Target Price | $5.63 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 861.8K | 370.7K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 52.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.20 | $88.12 |
| Revenue Next Year | $6.22 | $18.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $8.16 |
| 52 Week High | $4.67 | $73.06 |
Technical Indicators
Market Signals| Indicator | NCMI | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 26.00 |
| Support Level | $2.16 | N/A |
| Resistance Level | $3.72 | $14.39 |
| Average True Range (ATR) | 0.11 | 0.75 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 39.24 | 3.28 |
Price Performance
Historical ComparisonAbout NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.